MetaCap

Aurinia Pharmaceuticals (AUPH) vs Immunome (IMNM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aurinia Pharmaceuticals (AUPH) has outperformed Immunome (IMNM) over the past year, losing 6.3% versus a loss of 15.3%. Over five years, IMNM leads with a -7.5% price change compared with -24.0% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.85 billion), about 1.1 times the size.

Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -3060.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%IMNM-15.33%
+65%+23%-19%
Nov 21, 20251 yearNov 20, 2026
AUPH-48.37%IMNM-8.78%
+73%-11%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus IMNM key metrics
MetricAUPHIMNM
Share price$14.70$15.69
Market cap$1.97B$1.85B
1-day change-1.28%-5.54%
YTD return-7.84%-26.96%
1-year return-6.25%-15.33%
5-year return-23.95%-7.54%
P/E ratio (TTM)6.45—
Forward P/E12.67—
EPS (TTM)$2.28$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M$6.94M
Revenue growth (YoY)+20.38%-23.23%
Net income (latest FY)$287.20M$-212.39M
Gross margin88.46%—
Operating margin37.06%-3228.83%
Net margin101.47%-3059.99%
52-week high$19.25$30.06
52-week low$13.52$15.55
Distance from 52-week high-23.64%-47.80%
Analyst consensusbuystrong_buy
Avg. price target upside+25.85%+123.90%
Average volume858.74K1.36M
Shares outstanding134.00M118.07M
Employees128267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
  • Aurinia Pharmaceuticals grew revenue faster in its latest fiscal year (+20.38% vs -23.23%).

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Immunome

IMNM stock →

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees

AUPH vs IMNM FAQ

Which is bigger, Aurinia Pharmaceuticals or Immunome?

Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.85B for Immunome (IMNM).

Which stock has performed better over the past year, AUPH or IMNM?

AUPH returned -6.25% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.

Are Aurinia Pharmaceuticals and Immunome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons